IL-6 receptor blockers provided favorable recovery and visual improvement after acute attacks in #MOGAD and #AQP4NMOSD, but controlled trials are needed to determine effects on long-term disability. ja.ma/4gWEGrN
This is a hefty paper. In all, 21 (almost all composite) figures and 9 tables.
Perhaps my favourite is this one: being creative on the concept that you can re-threshold an established scale (mRS) using patient rated QoL……and that can significantly affect the results and conclusions of a study
Check it out ⬇️
In LGI1-antibody encephalitis, Ramanathan et al. identify immunotherapies associated with seizure resolution, reduced disability, and fewer relapses, and show how patient-rated outcome measures help define clinically significant disability. shorturl.at/Y1FMi
New clinical study. Published in @Brain1878
181 patients with LGI1-antibodies. #encephalitis. Multi-centre. International colleagues. Real world approach.
academic.oup.com/brain/advan…
3 of our Questions:
1. Which drugs / features associated with improved short term, disability and relapse outcomes?
2. Can we effectively re-threshold the modified Rankin Score (mRS)?
3. Do relapses associate with persistent disability and are there novel relapse biomarkers?
Our Main findings:
1. Seizures
- Stop with corticosteroids, plasma exchange. Not ASMs or IVIG.
- Recur with oral steroid (not ASM) weans
2. Long term disability (by mRS) - Can be re-thresholded to better reflect patient rated QoL (0-1, not 0-2)
- doing this, generates associations with immunotherapy timing: each day of delay matters, although not the specific immunotherapy
3. Relapses
- were common (37% of patients)
- associated with stepwise increases in mRS and greater overall disability
- rituximab associated with reduced relapse risk
- were associated with LGI1-IgM
We were very pleased with the depth (summarised in 8 main and 22 supplementary figures / tables) and detail of analyses
Collaboration with many including some on X @darshi_r@MackrillSamuel@antibodypad@Benjamin_Trewin
Exciting results from the TOMATO trial at #MSToronto2026 with an open label study by Zhang et al from China showing strong efficacy of tocilizumab in relapsing #MOGAD further supporting IL6 receptor blockade as an effective therapeutic target in #MOGAD👇
After both ECTRIMS2026 and American Neurological Association, I was reflecting on how #autoantibody-mediated neurological diseases are such precise clinical and biological entities. Few other diseases carry such homogeneity.
In 2023, @EoinFlanagan14@adrianbudhram1 and I proposed it would be better to split, rather than lump. We suggested that the antibody itself - especially when highly specific - should be the gateway to diagnosis.
The fundamental demographics, clinical features and biological characteristics differ so markedly (see table) based on the antigen
It’s a key theme across our two main 2026 reviews and calls for a rethink re nomenclature of these conditions.
thelancet.com/journals/lance…@TheLancetacademic.oup.com/brain/artic…@Brain1878
The autoantigen defines so so so much! It must be put at the center.
Delighted to share our international review on MRI Characteristics of #MOGAD! ➡️ Key imaging features are highlighted across the brain, optic nerves & spinal cord including lesion dynamics ➡️ Illustrative figures help show its full imaging spectrum👇
jamanetwork.com/journals/jam…
Happy to share @andreuvilaseca7 et al. observational #MOGAD study of IL-6R blockade across Americas showing low relapse rates similar to high-dose IVIG, supporting this therapeutic mechanism & globally available tocilizumab may expand access worldwide👇jamanetwork.com/journals/jam…
Multiple sclerosis is entering a new era: from controlling relapses to preventing progression. Progression independent of relapse activity means that disability can slowly accumulate even when there are no obvious attacks or new MRI lesions. This concept is reshaping how we think about multiple sclerosis (MS). Hauser describes in a new review paper in the The New England Journal of Medicine how our understanding of MS has evolved from a disease defined by relapses to one driven by both inflammation and neurodegeneration.
Key points:
- Epstein-Barr virus infection has emerged as one of the strongest environmental risk factors linked to MS development.
- Highly effective B cell therapies targeting CD20 can reduce new inflammatory lesions by approximately 99% and have transformed outcomes for relapsing MS.
- Despite these remarkable advances, silent progression and neurodegeneration continue in many individuals and these remain the field's greatest unmet challenge.
My take: This review captures one of the most important shifts in modern neurology. For years we celebrated preventing relapses and reducing MRI lesions. Those victories matter tremendously. However, the next frontier will be preventing progression, preserving brain reserve and repairing myelin before disability accumulates.
Here are 5 points that resonated w/ me:
1- MS is increasingly being understood as a disease that begins years before the first symptom appears.
2- The story of MS has evolved from a T cell disease to one where B cells occupy center stage.
3- Early use of highly effective therapies may alter the long-term trajectory of the disease.
4- Relapse control alone is no longer enough, and future therapies must tackle neurodegeneration and myelin repair.
5- The future of MS care will likely combine precision biomarkers, imaging, immune therapies and regenerative strategies aimed at keeping folks functioning and thriving for decades.
nejm.org/doi/full/10.1056/NE…#MS#multiplesclerosis
Key Point 1 from the article Treatment of Multiple Sclerosis by Drs. Ellen M. Mowry, Darin T. Okuda, and Daniel Ontaneda from the April #MultipleSclerosis and Related Disorders issue, which is available to subscribers at hubs.la/Q04dM8b60. #NeuroTwitter#MedEd
Key Point 7 from the article Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease by Eoin P. Flanagan and Cheryl Hemingway from the April #MultipleSclerosis and Related Disorders issue, which is available to subscribers at hubs.la/Q04ccJbT0. #NeuroTwitter#MedEd